Elucidation of


Journal

Drug metabolism and disposition: the biological fate of chemicals
ISSN: 1521-009X
Titre abrégé: Drug Metab Dispos
Pays: United States
ID NLM: 9421550

Informations de publication

Date de publication:
11 2019
Historique:
received: 27 03 2019
accepted: 07 09 2019
pubmed: 13 9 2019
medline: 29 5 2020
entrez: 13 9 2019
Statut: ppublish

Résumé

Endogenous substrates are emerging biomarkers for drug transporters, which serve as surrogate probes in drug-drug interaction (DDI) studies. In this study, the results of metabolome analysis using wild-type and Oct1/2 double knockout mice suggested that

Identifiants

pubmed: 31511257
pii: dmd.119.087262
doi: 10.1124/dmd.119.087262
doi:

Substances chimiques

Biomarkers 0
Organic Cation Transport Proteins 0
1-methyladenosine 15763-06-1
Creatinine AYI8EX34EU
Adenosine K72T3FS567

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1270-1280

Informations de copyright

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Takeshi Miyake (T)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Tadahaya Mizuno (T)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Issey Takehara (I)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Tatsuki Mochizuki (T)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Miyuki Kimura (M)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Shunji Matsuki (S)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Shin Irie (S)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Nobuaki Watanabe (N)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Yukio Kato (Y)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Ichiro Ieiri (I)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Kazuya Maeda (K)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Osamu Ando (O)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.).

Hiroyuki Kusuhara (H)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan (Tak.M., Tad.M., Tat.M., K.M., H.K.); Biomarker Department (I.T.) and Drug Metabolism & Pharmacokinetics Research Laboratories (N.W., O.A.), Daiichi-Sankyo Co., Ltd., Tokyo, Japan; Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan (M.K., S.M., S.I.); Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (Y.K.); and Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan (I.I.) kusuhara@mol.f.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH